Company Mabwell (Shanghai) Bioscience Co., Ltd.

Equities

688062

CNE100005RD2

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sales per region

Ratings for Mabwell (Shanghai) Bioscience Co., Ltd.

EPS Revisions

Annual profits - Rate of surprise

Sector Bio Therapeutic Drugs

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-05-07 pm EDT			5-day change	1st Jan Change
34.9 ^CNY	-2.79%		-1.33%	+6.76%

May. 07	Mabwell Announces FDA Grants Orphan Drug Designation to 9MW2821	CI
Apr. 29	Mabwell Bioscience Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Mabwell Shanghai Bioscience Co Ltd is a China-based company mainly engaged in the research and development, production and sales of therapeutic biological products. The Company's main businesses include the establishment of new varieties of drugs and the discovery of some early projects, the organization and development of preclinical research and pharmacological effects, and the development of drugs for preclinical research. The Company is also engaged in the organization, management and development of clinical trials of research species. The Company's research on drugs covers autoimmune, tumor, metabolism, ophthalmology, infection and other disease fields. The Company conducts business in domestic and foreign markets.

Number of employees: 1,491

CNY in Million	2022	Weight	2023	Weight	Delta
Technical Services 67.0 %	-	-	86	67.0 %	-
Antibody Drugs 32.9 %	-	-	42	32.9 %	-
Other 0.1 %	0	0.5 %	0	0.1 %	+13.44%

CNY in Million	2022	Weight	2023	Weight	Delta
Overseas 53.7 %	0	0.0 %	69	53.7 %	-
China 46.3 %	28	100.0 %	59	46.3 %	+113.22%

Managers	Title	Age	Since
Da Tao Liu CEO	Chief Executive Officer	52	17-06-30
Jin Hua DFI	Director of Finance/CFO	43	23-06-26
Xin Du CTO	Chief Tech/Sci/R&D Officer	52	20-05-31
Xun Gui BRD	Director/Board Member	38	19-05-31
Hui Guo Hu BRD	Director/Board Member	47	20-01-31
Xiang Hong Huang BRD	Director/Board Member	45	17-10-31
He Fei Wang IRC	Investor Relations Contact	-	-

Members of the board	Title	Age	Since
Bo Ling Li BRD	Director/Board Member	70	20-10-10
Chun Shan Tang BRD	Director/Board Member	55	19-03-31
Da Tao Liu CEO	Chief Executive Officer	52	17-06-30
Ning Xie BRD	Director/Board Member	62	17-06-30
Qian Zhao BRD	Director/Board Member	53	20-10-10
Jian Chu CHM	Chairman	57	17-04-30
Yue Yin BRD	Director/Board Member	41	18-02-28
Xiang Hong Huang BRD	Director/Board Member	45	17-10-31
Hui Guo Hu BRD	Director/Board Member	47	20-01-31
Xun Gui BRD	Director/Board Member	38	19-05-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	399,600,000	189,149,257 ( 47.33 %)	0	47.33 %

Name	Equities	%	Valuation
Hainan Shiyu Investment Management Co., Ltd. 7.651 %	15,424,468	7.651 %	75 M ¥
Jun Wu 5.495 %	11,077,422	5.495 %	54 M ¥
Haitong Innovation Securities Investment Co Ltd. 3.881 %	7,823,563	3.881 %	38 M ¥
Xin Su 3.295 %	6,642,911	3.295 %	32 M ¥
Shenzhen Oriental Fortune Capital Investment Mgmt Co. Ltd. 3.026 %	6,100,911	3.026 %	30 M ¥
Loyal Valley Capital Co. Ltd. 2.455 %	4,950,000	2.455 %	24 M ¥
Ganzhou Development Investment Fund Management Co. Ltd. 2.455 %	4,950,000	2.455 %	24 M ¥
Shenzhen Rongyu Capital Management Co., Ltd. 2.455 %	4,950,000	2.455 %	24 M ¥
Fullgoal Fund Management Co., Ltd. 2.320 %	4,677,607	2.320 %	23 M ¥
Founder Healthcare Fund Co., Ltd. 2.255 %	4,545,178	2.255 %	22 M ¥

Name	Equities	%	Valuation
Chun Shan Tang 71.92 %	140,560,000	71.92 %	681 M ¥
Ningbo Meishan Zhongjun Jianlong Investment Partnership LP 10.23 %	20,000,000	10.23 %	97 M ¥
Da Tao Liu 7.727 %	15,100,000	7.727 %	73 M ¥
Ningbo Meishan Pearl Investment Management Partnership LP 3.480 %	6,800,000	3.480 %	33 M ¥
Ning Xie 3.362 %	6,570,000	3.362 %	32 M ¥

Mabwell (Shanghai) Bioscience Co., Ltd.

Room 105, Building 2 230 Cailun Road

201210, Shanghai

http://www.mabwell.com

address Mabwell (Shanghai) Bioscience Co., Ltd.(688062)

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

34.9 CNY

Average target price

35.92 CNY

Spread / Average Target

+2.91%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
MABWELL (SHANGHAI) BIOSCIENCE CO., LTD.	+6.76%	1.93B
VERTEX PHARMACEUTICALS INCORPORATED	+2.93%	108B
ARGENX SE	+7.02%	23.46B
BIONTECH SE	-14.60%	21.72B
GENMAB A/S	-7.05%	18.64B
WUXI APPTEC CO., LTD.	-38.55%	17.45B
BEIGENE, LTD.	-8.83%	17.19B
NEUROCRINE BIOSCIENCES, INC.	+5.51%	13.99B
SAREPTA THERAPEUTICS, INC.	+37.49%	12.53B
VIKING THERAPEUTICS, INC.	+329.39%	8.81B

Bio Therapeutic Drugs